JMP Securities Reiterates “Market Outperform” Rating for DBV Technologies (NASDAQ:DBVT)

DBV Technologies (NASDAQ:DBVT)‘s stock had its “market outperform” rating reiterated by research analysts at JMP Securities in a report issued on Friday,Benzinga reports. They currently have a $10.00 price objective on the stock. JMP Securities’ target price would indicate a potential upside of 101.21% from the stock’s previous close.

Several other research analysts have also commented on DBVT. HC Wainwright lifted their price objective on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th. StockNews.com started coverage on shares of DBV Technologies in a report on Thursday. They issued a “hold” rating for the company.

DBV Technologies Price Performance

Shares of DBVT stock opened at $4.97 on Friday. The company has a market cap of $102.23 million, a PE ratio of -1.10 and a beta of 0.64. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $9.49. The stock’s 50 day simple moving average is $3.32 and its two-hundred day simple moving average is $3.82.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.